Knowthestock.com
BABY - Natus Medical, Inc.

Sell

Weak GrowthEarnings/Profit is Negative

28%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -15.13%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -4.39%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 2.02
Debt Ratio is 0.34
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.18
Cash Flow is MODERATE
Cash from Operations Growth is -52.81%
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Natus Medical, Inc. (BABY) - http://www.natus.com
Natus Medical, Inc. engages in the provision of newborn care, neurology, and hearing and balance assessment healthcare products and services. Its products are used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The company was founded by Maurizio Liverani, John Robert Camber Porter, William New, Jr., Brian Prinn and William W. Moore on May 26, 1987 and is headquartered in Pleasanton, CA.
Exchange - NASDAQ
Industry - Medical Specialties
Sector - Health Technology
CEO - Jonathan A. Kennedy
Employees - 1,729
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.